BioAgilytix Expands Hamburg Lab

Supporting Customer Drug Development from Early Phase to Market Authorization

BioAgilytix, a leading global bioanalytical lab, announced the expansion and GMP certification of its facility in Hamburg, Germany. The enhanced footprint and addition of world-class resources enable the company to increase the services offered to their clients throughout all phases of their drug development projects.

Frank Horling, PhD, Managing Director of BioAgilytix in Hamburg, cuts the ribbon. (Image: © BioAgilytix Europe GmbH)
Frank Horling, PhD, Managing Director of BioAgilytix in Hamburg, cuts the ribbon. (Image: © BioAgilytix Europe GmbH)

The enhanced footprint and addition of world-class resources enable the company to increase the services offered to their clients throughout all phases of their drug development projects.

Also, to further support clients in the European market, BioAgilytix has expanded its quantitative PCR (qPCR) assay development, validation, and sample analysis to the Hamburg facility. This initiative continues our support for gene and cell therapy programs at any phase of their development process. The company’s qPCR services include biodistribution, persistence, vector shedding, gene expression, and biomarker support.

BioAgilytix launches the Hamburg lab’s new competencies on the heels of another important achievement: certification of Good Manufacturing Practices (GMP) to perform Chemistry and Manufacturing Controls (CMC) testing. Achieving this milestone required the BioAgilytix quality system to undergo extensive evaluations and audits to show standard operating procedures (SOPs), facilities, and operational staff met or exceeded requirements. By expanding its early-stage-to-market-authorization GMP service to Europe, BioAgilytix complements the GMP services available in its Durham, North Carolina facility since 2010.

“With GMP-compliant laboratory locations now in the U.S. and Europe, BioAgilytix is well positioned to partner with clients around the world to offer a full suite of bioanalytical services in support of the global release, production, and manufacture of biologic drugs,” said Frank Horling, PhD, Managing Director of BioAgilytix in Hamburg. “In tandem with our recent leadership additions in Europe, these expanded capabilities and strengthened customer relationships will pave the way for further innovation and success in this vibrant market.”

On May 4, 2023, the BioAgilytix team and its customers celebrated the unveiling of the Hamburg lab with an official ribbon cutting. The event also included a tour of the facility and presentations on the new full-service offering.

More News

Olympus: Aufbau digitaler Exzellenzzentren weltweit

Olympus kündigt die Einführung einer Reihe von digitalen Exzellenz-Zentren (DECs) an. Der Schritt folgt der Übernahme von Odin Vision, einem Londoner Unternehmen im ...

Read more …

20 Jahre UKSH

Das Universitätsklinikum Schleswig-Holstein (UKSH) wurde am 2. Juni vor zwanzig Jahren gegründet. Die Fusion der beiden Universitätsmedizinstandorte in Kiel und Lübeck zum UKSH ...

Read more …
Henipavirus is a genus of viruses in the family Paramyxoviridae, containing six established species. They derive their name from two of these species, Nipah virus (pictured) and Hendra virus.
Henipavirus is a genus of viruses in the family Paramyxoviridae, containing six established species. They derive their name from two of these species, Nipah virus (pictured) and Hendra virus. (Credit: Cynthia Goldsmith)

Evotec erhält Förderung von Open Philanthropy

Evotec SE gab heute bekannt, dass das Unternehmen eine Förderung von 1,7 Mio. $ von Open Philantropy erhalten hat, einem philanthropischen Geldgeber, ...

Read more …